Letter by Kizawa et al Regarding Article, "Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study"

Circulation. 2020 Sep 15;142(11):e154-e155. doi: 10.1161/CIRCULATIONAHA.120.047232. Epub 2020 Sep 14.

Authors

Rika Kizawa¹, Tomohiko Hara², Yuji Miura¹

Affiliations

¹ Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan (R.K., Y.M.).
² Pharmaceuticals and Medical Devices Agency, Tokyo, Japan (T.H.).

PMID: 32924570
DOI: 10.1161/CIRCULATIONAHA.120.047232

No abstract available

Publication types

Letter
Comment

MeSH terms

Aromatase Inhibitors / adverse effects
Breast Neoplasms* / drug therapy
Breast Neoplasms* / epidemiology
Cardiovascular System*
Cohort Studies
Female
Humans
Tamoxifen

Substances

Aromatase Inhibitors
Tamoxifen